Biologics Licensing Application

News

Replimune has announced the FDA has issued a Complete Response Letter regarding the Biologics License Application for RP1 combined with nivolumab.

News

The FDA has named Dexcom as the first company to take part in its TEMPO pilot, which aims to bring digital health tech to patients more quickly.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.